Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;60(Suppl 3):9-15.
doi: 10.20471/acc.2021.60.s3.01.

FALSE PHARMACORESISTANCE - A TRUE PROBLEM

Affiliations
Review

FALSE PHARMACORESISTANCE - A TRUE PROBLEM

Silvio Bašić et al. Acta Clin Croat. 2021 Dec.

Abstract

Pharmacoresistant epilepsy poses a great burden to patients, their families, and the whole healthcare system, with numerous social, economic, physical, and psychical consequences. Hence, it is a diagnosis that has to be made only in cases of high certainty, after all potential causes of epilepsy have been evaluated. One of the important causes of pharmacoresistant epilepsy is false pharmacoresistance, an entity that implies a condition in which poor disease control is not a consequence of the biology of the disease itself, antiepileptic drug inefficacy, and/or patient specificity. It is a consequence of human error and strongly depends on the experience of the treating physician, as well as on the attitude of the patient. Despite its 'falseness', this entity is accompanied by real consequences for the patient and his family, and at the same time, it delays appropriate treatment of the actual disease from which the patient is suffering. In order to introduce appropriate treatment and avoid unnecessary and harmful diagnostic procedures, false pharmacoresistance is a condition that has to be ruled out in any patient with difficult-to-treat seizures.

Keywords: Antiepileptic drugs; Epilepsy; False pharmacoresistance; Pharmacoresistant epilepsy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Basic S. Epilepsy pharmacoresistance – where are we now? J Neurol Stroke. 2016;4(6):00161. 10.15406/jnsk.2016.04.00161 - DOI
    1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77. 10.1111/j.1528-1167.2009.02397.x - DOI - PubMed
    1. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure. 2002;11(2):77–84. Epub 2002/04/12.10.1053/seiz.2002.0593 - DOI - PubMed
    1. Beghi E. Addressing the burden of epilepsy: many unmet needs. Pharmacol Res. 2016;107:79–84. Epub 2016/03/10.10.1016/j.phrs.2016.03.003 - DOI - PubMed
    1. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919–26. Epub 2011/09/09.10.1056/NEJMra1004418 - DOI - PubMed

Substances